#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chordoma Lupus nephritis Primary hyperoxaluria Cutaneous T-cell lymphoma stage I Gastric cancer Congenital hypotransferrinaemia Langerhans' cell histiocytosis Hodgkin's disease refractory Inflammatory myofibroblastic tumour Monogenic diabetes Aspergillus infection Acquired C1 inhibitor deficiency Non-Hodgkin's lymphoma unspecified histology indolent Vascular malformation Rhabdoid tumour More trials…

    Learn about Rare Diseases

    Sarcoma – Treatment Hereditary angioedema – Treatment Turner’s syndrome Pelizaeus-Merzbacher disease – Diagnostics Friedreich’s ataxia – Diagnostics Paraneoplastic neurological syndrome – Treatment Waldenstrom’s macroglobulinaemia recurrent – Diagnostics Krabbe’s disease – Trials in Disease Medulloblastoma – Life with Disease CADASIL – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Levodopa Metoclopramide VAMIFEPORT TRIHYDROCHLORIDE Protein C Ruxolitinib Romiplostim Colesevelam Disodium Folinate MARALIXIBAT Tamoxifen Citrate Oxybuprocaine Hydrochloride Tumor Necrosis Factor-Alpha HSP-CAR30 Glasdegib Imipenem Monohydrate R3R01 ALXN2420 Repotrectinib Degarelix Acetate Avapritinib More therapies…

    Learn about Your Condition

    Epidermolysis bullosa Arterial stiffness Head injury Dry mouth Hyperparathyroidism primary Myopia Intestinal obstruction Deafness bilateral Cervix carcinoma stage II Anaemia of pregnancy Chronic disease Overweight Wolfram syndrome Clinically isolated syndrome Skin papilloma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hidradenitis

  • A study to evaluate the effectiveness and safety of zasocitinib in patients with moderate to severe hidradenitis suppurativa

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Zasocitinib
    France Germany The Netherlands Poland

  • Study to measure bimekizumab concentration in breast milk of breastfeeding mothers with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurativa

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Bimekizumab
    Germany Spain

  • Study on Fecal Microbiota Transplantation and Amoxicillin-Clavulanic Acid for Patients with Moderate to Severe Hidradenitis Suppurativa

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Allogeneic Faecal Microbiota
    France

  • Study on the Use of Adipose-Derived Stem Cells for Treating Hidradenitis Suppurativa in Patients with Draining Fistulas

    Not yet recruiting

    1 1
    Investigated Drugs:
    • Allogeneic Adipose-Derived Adult Mesenchymal Stem Cells Expanded
    Spain

  • A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    2 1
    Germany Greece Poland Spain

  • Study of Tibulizumab to Treat Adults with Hidradenitis Suppurativa

    Not recruiting

    2 1
    Investigated Diseases:
    • Hidradenitis
    Germany Hungary Poland Spain
Previous Page
1 2 3 4 5 … 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!